Nanomol Technologies is also active in several European and National Collaborative projects. Specifically, NANOMOL Technologies has been involved in several consortia to carry out the following R+D projects dealing with the application of Micro and Nanotechnology to biomedical and health care purposes:
Nanonafres project consist of a multidisciplinary consortium of seven Catalan partners, including public scientific research centres, small companies, primary care centres and public hospitals with the aim to develop a novel pharmaceutical formulation that integrates a marketed free recombinant human Epidermal Growth Factor (rh-EGF) in nanovesicles (NV-rh-EGF) to enable its topical administration and promote wound healing of venous leg ulcers. The Project was granted in October 2016 with a financial programme (RIS3CAT) by the Generalitat of Catalonia (FEDER funds), which is aligned with the European Commission (EC) National/Regional Research and Innovation Strategies for Smart Specialisation (RIS3 strategies). This project is part of the TECSALUT RIS3CAT community coordinated by LEITAT Technology Center. Nanonafres project is expecting to last for 42 months and will carry out pharmaceutical development of the new nanoformulation required to perform nonclinical testing as well as a clinical study in patients with venous leg ulcers to establish the safety of NV-rh-EGF and an obtain an efficacy preliminary proof of concept. Within this framework, Nanomol Technologies is the Leader and Technological Partner of the Nanonafres Project.
Smart-4-Fabry (S4F) is the acronym of a H2020 funded Project that stands for “Smart functional GLA-nanoformulation for Fabry disease”. Smart-4-Fabry is a collaborative Project funded under the H2020 EU Research and Innovation programme, and started on the 1st January 2017 and will last four years. The S4F Project has been conceived to obtain a new nanoformulation of GLA, that will improve the efficacy and tolerability of this new drug in comparison to the actual treatment for Fabry Disease with non-formulated GLA. In the case of the Fabry Disease (FD), the deficiency of α-Galactosidase A (GLA) enzyme result in the cellular accumulation of neutral glycosphingolipids, leading to widespread vasculopathy with particular detriment to the kidneys, heart and central nervous system. The final benefit expected with S4F project will be seen as considerable reduction on the Fabry disease treatment costs and a substantial improvement in the efficacy of GLA enzyme, together with life-quality of Fabry disease patients. In this Project, Nanomol Technologies is involved in pharmaceutical develpment of the new reformulated GLA based drug, scale-up of the technology which permits to produce the new nanoformulation, and GMP implementation of a pilot productive line to obtain the new nanoformulation for future clinical testing.
The idea of TheraGlio FP7 Cooperation project is to develop a multimodal imaging system for Theranostics (therapy+diagnosis) of patients bearing malignant glioma, the most common primary brain tumour. This technology will avail of new generation Microbubbles (MBs), in which development NANOMOL Technologies is involved, that can simultaneously act as drug delivery system and contrast agent for Magnetic Resonance Imaging, intra-operative Contrast-Enhanced Ultrasound and intra-operative fluorescence microscopic.
The main target of this ITN network is the education of a new generation of scientists for the development, via breakthrough research, of two technologically relevant applications, namely two-photon microscopy (2PM) and two-photon polymerization (2PP), with enormous applicative potential in bioimaging, biomedicine, and rapid prototyping techniques. In this ITN, NANOMOL Technologies is involved in the scaling-up of Organic Nanoparticles (ONP) production processes to be used in photonic applications.